# Annexon to Present at the Bank of America Securities Health Care Conference 2026
Canonical URL: https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-bank-of-america-securities-health-care-conference-2026
Ticker: ANNX
Company: Annexon, Inc.
Source: Annexon, Inc.
Published: 2026-05-06 12:00 EST
Original Source URL: https://ir.annexonbio.com
## Summary

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,

## Article Body
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,
## Recent Company News
- 2026-05-27 12:00 EST — [Annexon to Participate in Upcoming June Investor Conferences](https://biopharmsignal.com/news/ANNX/annexon-to-participate-in-upcoming-june-investor-conferences) — Source: Annexon, Inc.
- 2026-05-07 20:01 EST — [Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-first-quarter-2026-financial-results-portfolio-progress-and-key-anticipated-milestones) — Source: Annexon, Inc.
- 2026-05-06 12:00 EST — [Annexon to Present at the Bank of America Securities Health Care Conference 2026](https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-bank-of-america-securities-health-care-conference-2026) — Source: Annexon, Inc.
- 2026-04-08 20:05 EST — [Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Annexon, Inc.
- 2026-03-30 20:01 EST — [Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and-key-anticipated-milestones) — Source: Annexon, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)